Dear everybody, welcome to the newsletter. We are today at NASDAQ in New York. We are basically spending some time here in New York to give a number of interviews, both for written media and recorded media. You will, for example, see us at the NASDAQ news channel at some point in the future because of today's work. And other than that, we have been to a number of conferences, basically, where we were invited to come and introduce ourselves to circles of investors that otherwise wouldn't have heard about us. So spending some good time here and feeling very welcome both by NASDAQ, but also the investor community. People are very intrigued about what we are building overall, but specifically, NCT as a business opportunity is something that is really fascinating people and we are getting a lot of really good interactions on that. As we are starting to get recognized as super users of AI in the pharmaceutical industry, I was invited to a panel, together with a number of pharmaceutical companies and other people from the industry, to have a conversation about how we uniquely utilize this ability to calculate via the AI algorithms, what mutations leads to better enzymes that leads to better small molecules, and this ability to make return on investments on the efforts of AI and why we are uniquely positioned, because we can generate a lot of data to feed the algorithms and really optimize these reinforcements, a. AKA training loops that are very needed when you use these kinds of technologies. We'll be having our earnings call on November 13th, that's Thursday, and we are looking forward to giving an overview of the quarter in hindsight and where we are going with the company. For that reason, we will also limit a little bit the amount of news we are releasing in this newsletter, and just to set expectations, we will probably be doing 10 newsletters a year, and we are of course very flattered that people started yanking us a little bit when it's more than four weeks since we have had the last newsletter, what's going on we would like to follow. So stay tuned here, we will give updates as often as we can, but the next real update is going to be the earnings call.